srch

We strive to balance these two complementary and vital goals in all that we do. To learn more about our clinical trials, visit blueprintclinicaltrials.com or contact us in the U.S. at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768), and in Europe at medinfoeurope@blueprintmedicines.com or +31 85 064 4001. Our clinical trials.

1 dag siden · Blueprint Medicines Completes Acquisition of Lengo Therapeutics - Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting ...

Rapidly advance our lead drug candidates, BLU-285 and BLU-554, through clinical development. •: Build a pipeline of kinase drugs for genomically-defined drivers ...

19 rader · 01.12.2021 · Pipeline | Blueprint Medicines. An expansive pipeline. We are focused on the rapid design and development of precision therapies for people with cancer and rare diseases. Rapidly advancing pipeline. Genomically defined cancers. Genomically defined cancers. Molecular target.

US precision cancer therapy specialist Blueprint Medicines (Nasdaq: BPMC) today announced that it has entered into a definitive agreement ...

An expansive pipeline. We are focused on the rapid design and development of precision therapies for people with cancer and rare diseases.

Through this acquisition, Blueprint Medicines will add LNG-451, ... undisclosed preclinical precision oncology programs to its pipeline.

Blueprint Medicines | 23408 followers on LinkedIn. ... to rapidly and reproducibly translate science into a broad pipeline of precision therapies.

Transformative science, targeted medicines ... We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better ...

Blueprint Medicines, a precision therapy company, is advancing a deep pipeline of targeted therapies focused on genomically defined cancers, rare diseases ...

The acquisition adds Lengo's EGFR inhibitor LNG-451 to Blueprint's pipeline, which already includes two other investigational EGFR ...

4 timer siden · Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing ...

People diagnosed with GIST should be tested for mutations to determine which type of therapy might be right for them. Blueprint Medicines is developing avapritinib as a potential treatment for patients with PDGFRA exon 18 mutant GIST globally. View approved uses of avapritinib. View clinical trials of avapritinib.

1 dag siden · Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a ...

Blueprint Medicines is paying $250 million up front to acquire Lengo ... The Blueprint pipeline also includes two drug candidates for NSCLC ...